Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

252 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma

NCT04566887

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • BC Cancer Agency Vancouver, British Columbia, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
  • Sunnybrook Research Institute Toronto, Ontario, Canada
View Trial Details
Active, not recruiting

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
View all 418 locations
View Trial Details
Active, not recruiting

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

NCT06504199

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
  • Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China
View Trial Details
Active, not recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details

Related conditions